Efeitos adversos da poliquimioterapia para hanseníase: utilização de doses alternativas e avaliação pós alta

Kubota, Rosina Maria Martins; Brancini, Viviane Cristina L; Gouveia, Aline S; Nardi, Susilene Maria Tonelli; Paschoal, Vania Del'Arco; Vendramini, Silvia Helena Figueiredo.
Hansen. int ; 39(1): 8-21, 2014. tab, ilus
Artigo em Português | LILACS, SES-SP | ID: biblio-831057

Documentos relacionados

  1. Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis.
  2. Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy.
  3. Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur).
  4. Adverse effects of polychemotherapy for leprosy in 13 years of follow-up at a university hospital.
  5. Leprosy treatment during pregnancy and breastfeeding: A case report and brief review of literature.
  6. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
  7. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
  8. HLA-B*13:01 and the dapsone hypersensitivity syndrome.
  9. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
  10. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.